ACUT (Accustem Sciences) Risk Assessment


ACUT Accustem Sciences Inc ACUT
27 GF Score
Price $0.19
! 1 Warning Sign
View Full Analysis

What is Accustem Sciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Accustem Sciences is: No Data: Cannot be evaluated.

Accustem Sciences  (OTCPK:ACUT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Accustem Sciences Risk Assessment Related Terms

ACUT vs DCOY, BIXT, SPRC: Risk Assessment Comparison

For the Biotechnology subindustry, Accustem Sciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accustem Sciences Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's Risk Assessment falls into.


ACUT
27GF Score
Accustem Sciences Inc ACUT
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accustem Sciences Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10001
Accustem Sciences Inc is a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people who are diagnosed with cancer each year. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services.
27GF Score

Get the complete analysis for ACUT

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price